The 10-second takeaway
For the quarter ended June 30 (Q2), Optimer Pharmaceuticals beat expectations on revenues and exceeded expectations on earnings per share.
Compared to the prior-year quarter, revenue expanded significantly and GAAP loss per share dropped.
Margins increased across the board.
Optimer Pharmaceuticals recorded revenue of $49.8 million. The 11 analysts polled by S&P Capital IQ hoped for a top line of $44.6 million on the same basis. GAAP reported sales were much higher than the prior-year quarter's $.0 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
EPS came in at -$0.01. The 11 earnings estimates compiled by S&P Capital IQ predicted -$0.05 per share. GAAP EPS were -$0.01 for Q2 against -$0.52 per share for the prior-year quarter.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the quarter, gross margin was 91.9%, 3,174,510 basis points better than the prior-year quarter. Operating margin was 0.7%, 7,515,300 basis points better than the prior-year quarter. Net margin was -0.6%, 7,281,060 basis points better than the prior-year quarter.
Next quarter's average estimate for revenue is $26.6 million. On the bottom line, the average EPS estimate is -$0.44.
Next year's average estimate for revenue is $111.8 million. The average EPS estimate is -$1.21.
The stock has a two-star rating (out of five) at Motley Fool CAPS, with 112 members out of 147 rating the stock outperform, and 35 members rating it underperform. Among 52 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 37 give Optimer Pharmaceuticals a green thumbs-up, and 15 give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Optimer Pharmaceuticals is buy, with an average price target of $19.50.
The drug and health-care investing landscape is littered with also-rans and a few major winners. Is Optimer Pharmaceuticals the right stock for you? Read "Discover the Next Rule-Breaking Multibagger" to learn about a company David Gardner believes will be a phenomenal success over the next few years. Get instant access to this free report.
- Add Optimer Pharmaceuticals to My Watchlist.
Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is the co-advisor of Motley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. The Motley Fool has no positions in the stocks mentioned above. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.